Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC).

4062Background: Cetuximab is an EGFR-targeting IgG1 mAb. Pre-clinical data suggests cetuximab induces CD8+ cytotoxic T-cell (CTL) infiltration of tumors. We hypothesized that augmentation of CTLs i...